Treatment for multiple sclerosis (MS) patients will improve in the next ten years, according to a new report.
The Target Multiple Sclerosis report, produced by the Association of the British Pharmaceutical Industry (ABPI), claims that there has been "astonishing" growth in MS research over the past ten years and "there are good reasons for optimism", reports Medical News Today.
It stated that a number of new therapies are in the later stages of development.
These include oral medications which would reduce the need for frequent self-injections, giving patients an improved quality of life.
"Multiple sclerosis is an excellent example of how advances in medicines are usually made in steps," said Dr Richard Barker, director general of the ABPI.
"It's just a dozen years since the first medicine to treat MS was licensed and now there are a large number of these in development."
Meanwhile, the Multiple Sclerosis Society has welcomed a move by the Medicines and Healthcare Products Regulatory Agency to provide potential providers of the unlicensed medication Sativex with more information to help them with their decision.
The oral spray is currently the subject of clinical trials to assess its effect on alleviating pain in MS patients.
Please click here for advice abou finding the right type of care.